Shionogi traded at 6,887.00 this Wednesday May 25th, decreasing 7.00 or 0.10 percent since the previous trading session. Looking back, over the last four weeks, Shionogi lost 0.85 percent. Over the last 12 months, its price rose by 21.66 percent. Looking ahead, we forecast Shionogi to be priced at 6,568.73 by the end of this quarter and at 5,934.12 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
6,887.00
Daily Change
-0.10%
Yearly
21.66%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
M3 Inc 3,813.00 -47.00 -1.22% -47.70%
Kyowa Hakko Kirin 2,740.00 6.00 0.22% -18.45%
Takeda 3,780.00 -17.00 -0.45% 0.99%
Astellas Pharma 2,006.00 17.00 0.85% 20.73%
Sumitomo Dainippon 1,072.00 -10.00 -0.92% -49.62%
Shionogi 6,887.00 -7.00 -0.10% 21.66%
Chugai Pharma 3,537.00 -14.00 -0.39% -14.32%
Eisai 5,399.00 -43.00 -0.79% -22.90%
Terumo 4,151.00 27.00 0.65% -0.72%
Daiichi Sankyo 3,389.00 19.00 0.56% 32.02%
Otsuka Holdings 4,460.00 -7.00 -0.16% -0.22%

Indexes Price Day Year
JP225 26678 -70.34 -0.26% -6.86%

Shionogi
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.